Our finding, along with the previous studies concerning the important roles of AGAP2-AS2 in non–small-cell lung cancer and gastric cancer suggested that AGAP2-AS2 could serve as a new biomarker with early diagnostic and therapeutic value. The gene discussed is AGAP2; the disease is lung cancer.